By harnessing the power of synthetic biology, the SynThera project aims to close this gap by developing therapeutic microorganisms that are suitable to target multi-drug resistant pathogens at their site of infection, as well as to individualize and improve existing prophylactic treatment strategies. Thus, SynThera holds the potential to transform antimicrobial therapies by offering personalized solutions to combat multi-drug resistant pathogens

SynThera addresses the urgent societal need of lacking novel antiinfective strategies by using the timely and promising approach to develop synthetic microorganisms for efficient, tailored treatments of infections. New personalized antimicrobial therapies are particularly required to counteract the increase in antibiotic resistance among pathogenic bacteria and fungi. To this end, SynThera brings together an interdisciplinary consortium of scientists with proven expertise in the fields of microbiology, systems biology, infection biology and natural product research. We are looking forward to accompanying this project and supporting the researchers by using our complementary expertise both in academia and industry to provide advice on the developed concepts and technology.